Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 136 | 2.230 |
Why?
|
| Coronary Disease | 9 | 2015 | 49 | 1.630 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 42 | 1.420 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 270 | 1.400 |
Why?
|
| Cisplatin | 2 | 2023 | 54 | 1.370 |
Why?
|
| Secondary Prevention | 5 | 2020 | 49 | 1.240 |
Why?
|
| Cardiology | 5 | 2021 | 34 | 1.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 198 | 1.220 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 4 | 1.080 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 536 | 1.070 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.820 |
Why?
|
| Aniline Compounds | 2 | 2020 | 32 | 0.810 |
Why?
|
| Heart Failure | 7 | 2021 | 118 | 0.770 |
Why?
|
| Exercise Test | 3 | 2018 | 57 | 0.770 |
Why?
|
| Carboplatin | 1 | 2021 | 25 | 0.700 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 5 | 0.700 |
Why?
|
| Benzimidazoles | 1 | 2021 | 9 | 0.700 |
Why?
|
| Paclitaxel | 1 | 2021 | 48 | 0.700 |
Why?
|
| Humans | 38 | 2023 | 24703 | 0.700 |
Why?
|
| Standard of Care | 1 | 2020 | 8 | 0.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 232 | 0.680 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 6 | 0.650 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 12 | 0.630 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 6 | 0.600 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 1 | 0.580 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.580 |
Why?
|
| Life Style | 3 | 2019 | 174 | 0.580 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 157 | 0.580 |
Why?
|
| Mutation | 1 | 2019 | 307 | 0.570 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 37 | 0.560 |
Why?
|
| Apoptosis | 2 | 2022 | 197 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 244 | 0.540 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.540 |
Why?
|
| Taxoids | 1 | 2017 | 11 | 0.540 |
Why?
|
| ErbB Receptors | 3 | 2023 | 49 | 0.520 |
Why?
|
| Cell Proliferation | 1 | 2017 | 167 | 0.510 |
Why?
|
| Neoplasms | 1 | 2018 | 213 | 0.490 |
Why?
|
| Aged | 19 | 2023 | 8382 | 0.490 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 29 | 0.450 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 116 | 0.450 |
Why?
|
| Middle Aged | 16 | 2021 | 8294 | 0.430 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 89 | 0.430 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 20 | 0.430 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 39 | 0.420 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 374 | 0.400 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 9 | 0.400 |
Why?
|
| Male | 18 | 2023 | 13669 | 0.390 |
Why?
|
| Depression | 2 | 2015 | 390 | 0.370 |
Why?
|
| Female | 17 | 2021 | 14048 | 0.360 |
Why?
|
| Critical Pathways | 1 | 2011 | 17 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 15 | 0.350 |
Why?
|
| Program Evaluation | 3 | 2017 | 112 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 286 | 0.330 |
Why?
|
| Prognosis | 4 | 2021 | 674 | 0.330 |
Why?
|
| Chest Pain | 1 | 2009 | 16 | 0.320 |
Why?
|
| Mass Screening | 1 | 2011 | 165 | 0.320 |
Why?
|
| Australia | 8 | 2021 | 24 | 0.310 |
Why?
|
| Smartphone | 2 | 2021 | 13 | 0.310 |
Why?
|
| Medication Adherence | 1 | 2009 | 35 | 0.310 |
Why?
|
| Models, Statistical | 1 | 2009 | 123 | 0.310 |
Why?
|
| Risk Factors | 9 | 2019 | 2099 | 0.300 |
Why?
|
| Exercise Therapy | 2 | 2021 | 82 | 0.290 |
Why?
|
| Young Adult | 4 | 2021 | 1847 | 0.280 |
Why?
|
| Quality of Life | 4 | 2021 | 541 | 0.270 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.260 |
Why?
|
| Adult | 7 | 2021 | 7255 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 35 | 0.230 |
Why?
|
| Prospective Studies | 5 | 2018 | 1612 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 32 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 28 | 0.210 |
Why?
|
| Cetuximab | 1 | 2023 | 5 | 0.210 |
Why?
|
| Counseling | 2 | 2017 | 40 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.190 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 35 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 57 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4509 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2019 | 532 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2021 | 32 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 162 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 118 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3156 | 0.170 |
Why?
|
| Comorbidity | 4 | 2021 | 447 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 41 | 0.160 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 3 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 5 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 55 | 0.160 |
Why?
|
| Walking Speed | 1 | 2019 | 36 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 27 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3208 | 0.160 |
Why?
|
| Diastole | 1 | 2019 | 23 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 25 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 13 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 24 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 31 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 4 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 55 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 412 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 166 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 520 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 75 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2019 | 71 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 12 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 15 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 190 | 0.150 |
Why?
|
| Pharynx | 1 | 2018 | 11 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 66 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 35 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 56 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 399 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 29 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 413 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 22 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 199 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 124 | 0.130 |
Why?
|
| Health Behavior | 3 | 2021 | 154 | 0.130 |
Why?
|
| United States | 3 | 2018 | 1873 | 0.130 |
Why?
|
| Blotting, Western | 1 | 2017 | 140 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 421 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 26 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 144 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 182 | 0.120 |
Why?
|
| Calcium | 1 | 2017 | 334 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2015 | 167 | 0.110 |
Why?
|
| New Zealand | 3 | 2020 | 11 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 158 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 57 | 0.090 |
Why?
|
| Family Practice | 1 | 2009 | 14 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 36 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 74 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 5 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 14 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 24 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 24 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 81 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 49 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 15 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 49 | 0.080 |
Why?
|
| Prevalence | 1 | 2009 | 411 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 697 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 12 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2006 | 26 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1327 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 285 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 58 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 22 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 6 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 12 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 16 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 23 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 31 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 40 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 55 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 48 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 31 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 6 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 3 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 9 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 12 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 294 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 183 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 370 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 135 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 292 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 86 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 16 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 613 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 62 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 55 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 130 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 131 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 97 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 145 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 16 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 31 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 443 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 367 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 201 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 118 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 231 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 88 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 71 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 728 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 13 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1671 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 99 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 814 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 555 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 280 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 135 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 183 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1748 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 26 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 27 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 20 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 57 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 196 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 12 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 24 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 21 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 114 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 104 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 25 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 52 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 125 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 243 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 304 | 0.010 |
Why?
|
| Hypertension | 1 | 2002 | 169 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 150 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 280 | 0.010 |
Why?
|